With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development. Due to their higher physiological similarity to humans, these models are particularly valuable in the research of cardiovascular diseases, metabolic disorders, inflammatory immune diseases, and neurological diseases.
To assist clients in precisely selecting suitable large animal models, Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform. This platform focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs, and offers comprehensive and in-depth disease model development and pharmacodynamic research. The platform is equipped with world-class experimental facilities and equipment and is supported by a team of experienced scientists and technical experts. This professional team provides pharmacodynamic research services, including experimental protocol design, model establishment, and data analysis, to accelerate the translation of scientific research results into clinical applications.
The Medicilon Large Animal Pharmacodynamic Research Service Platform encompasses a wide range of disease models, including but not limited to metabolic diseases (such as obesity, diabetes, and hyperuricemia), cardiovascular diseases (such as thrombosis, stroke, and atherosclerosis), inflammatory and immune diseases (such as arthritis, osteoporosis, and psoriasis), as well as other disease models. This comprehensive coverage addresses nearly all major disease areas in current drug development.
The platform not only offers standard disease model development services but is also skilled in customizing complex disease models to meet the diverse research needs of clients. In addition, the platform provides a full range of services from drug screening and efficacy evaluation to safety assessment, helping clients accelerate the new drug development process.
For more info, contact:
Email: marshalma@medicilon.com Tel: +44 1223981791
Global Headquarters: 585 Chuanda Road, Pudong, Shanghai, 201299, China
UK Office: Ailla Future Business Centre, King's Hedges Road Cambridge, CB4 2HY
